ONWARD Medical N.V. has successfully closed a €40.6 million private placement with institutional investors, enhancing its capacity to develop innovative neurotechnology solutions aimed at restoring movement and independence for individuals with spinal cord injuries (SCI). The newly issued shares are now listed on Euronext Brussels, Amsterdam, and Paris, marking a significant milestone for the company as it continues to advance its proprietary ARC Therapy.

The significance of this funding lies in ONWARD’s commitment to addressing critical unmet needs in the SCI community. The company’s ARC-EX® System, already cleared for commercial use in the US and Europe, demonstrates promising efficacy in restoring voluntary movement. Furthermore, ONWARD is developing the ARC-IM® implantable system, which aims to manage blood pressure instability following spinal cord injuries. This system is designed to integrate with brain-computer interfaces (BCI) and artificial intelligence (AI), potentially revolutionizing approaches to movement restoration through thought-driven mechanisms.

This development underscores a critical shift in the landscape of neurorehabilitation research and therapy. The successful funding not only accelerates the timeline for bringing these advanced therapies to market but also reinforces the importance of integrating cutting-edge technologies like BCI and AI into clinical applications. As ONWARD Medical continues to innovate, it sets a precedent for future research and development in the field, highlighting the potential for transformative therapies that could significantly enhance healthspan and quality of life for individuals affected by SCI.

Source: globenewswire.com